Neuro-oncology

Chimerix Inc. focuses on clinical research in H3 K27M-mutant diffuse glioma, a molecularly defined form of brain cancer within the field of central nervous system oncology.

• Diffuse glioma
• H3 K27M mutation
• Malignant glioma

The sponsor’s active trial landscape is centered on treatment after radiotherapy for this aggressive glioma subtype, with research activity extending across multiple collaborating sites in several countries.